Chronic hepatitis B
Conditions
Interventions
Study Group:The study group continued the original Peg-IFN-a-2b and/or nucleoside antiviral regimen plus wash-grade enteric bacterial capsule(50 ml/time, once every 4 weeks, no more than 3 times)
Control group:Peg-ifn-a-2b and/or nucleoside antiviral regimens are supplemented with a placebo
Sponsors
The First Affiliated Hospital of Fujian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Patients with chronic hepatitis B (CHB-RRB- who were willing to sign an informed consent form; according to the diagnostic criteriaCHB CHB in the guidelines for the prevention and treatment of chronic hepatiBis b (2022 edition) : chronic inflammatory disease of the liver caused by persistHBV HBV infection; 2. Age 18-60 years; 3. HBeAg-negative CHB treated with Peg-IFN-a-2b or NAs alone in combination with Peg-IFN-a-2b antiviral Patients, regularly treated for 24 weeks or more, currently 0.05 IU/ml<= HBsAg <500 IU/ml, or HBsAg<0.05 IU/ml but Anti-HBs<10 IU/ml; 4. No contraindications for interferon treatment, willing to continue Peg-IFN-a-2b treatment and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. HIV infection, Hepatitis A, C, D, E virus infection, drug-induced liver disease, alcoholic liver disease, autoimmune diseases, etc. 2. Patients who fail to receive regular treatment for reasons such as intolerance of interferon side effects or compliance. 3. Patients with liver cancer, lung cancer, lymphoma and other malignant tumors; 4. Pregnant or lactating women 5. Oral or intravenous antimicrobial agents 6. Blood CD4 + cells were less than 200 × 10^6/ml.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBsAg Clearance; | — |
Secondary
| Measure | Time frame |
|---|---|
| HBsAb positive conversion rate; | — |
Countries
China
Contacts
Public ContactPan Jinshui
The First Affiliated Hospital of Fujian Medical University
Outcome results
None listed